Cargando…
Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?
In December 2019, many pneumonia cases with unidentified sources appeared in Wuhan, Hubei, China, with clinical symptoms like viral pneumonia. Deep sequencing analysis of samples from lower respiratory tract revealed a novel coronavirus, called 2019 novel coronavirus (2019-nCoV). Currently there is...
Autores principales: | Sureda, Antoni, Alizadeh, Javad, Nabavi, Seyed Fazel, Berindan-Neagoe, Ioana, Cismaru, Cosmin Andrei, Jeandet, Philippe, Łos, Marek J., Clementi, Emilio, Nabavi, Seyed Mohammad, Ghavami, Saeid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297682/ https://www.ncbi.nlm.nih.gov/pubmed/32561291 http://dx.doi.org/10.1016/j.ejphar.2020.173288 |
Ejemplares similares
-
Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
por: Habtemariam, Solomon, et al.
Publicado: (2020) -
Game of “crowning” season 8: RAS and reproductive hormones in COVID-19 – can we end this viral series?
por: Cismaru, Andrei Cosmin, et al.
Publicado: (2020) -
Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID‐19: Shoot the messenger!
por: Habtemariam, Solomon, et al.
Publicado: (2020) -
COVID-19 and antimalarials. Have we been doing it wrong all along?
por: Cismaru, Cosmin Andrei, et al.
Publicado: (2021) -
Rationale for Effective Prophylaxis Against COVID‐19 Through Simultaneous Blockade of Both Endosomal and Non‐Endosomal SARS‐CoV‐2 Entry into Host Cell
por: Nabavi, Seyed Fazel, et al.
Publicado: (2021)